CanVirex

CanVirex is a Swiss biotechnology company focused on developing next-generation oncolytic virus therapies to treat various forms of cancer. The company's core technology is based on a proprietary measles virus platform that enables the selective destruction of tumor cells and the induction of a potent anti-tumor immune response. Originally a spin-off from the National Center for Tumor Diseases (NCT) and the German Cancer Research Center (DKFZ), CanVirex leverages deep expertise in virology and immunology. In July 2020, the company was acquired by Boehringer Ingelheim, integrating its innovative platform into the larger pharmaceutical company's oncology portfolio. This acquisition aims to combine CanVirex's viral vector technology with other immune-modulatory agents to improve outcomes for patients with hard-to-treat solid tumors.